Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units: A Randomized, Controlled, Cluster, Crossover Clinical Trial

Healthcare-associated infections (HAIs) remain a major problem in intensive care units (ICUs), driven by environmental contamination with multidrug-resistant organisms that persist despite routine manual cleaning. While hydrogen peroxide aerosolization and ultraviolet-C light devices have shown promise in reducing surface contamination, current evidence is inconsistent, mostly derived from single-center studies, and rarely linked to patient-centered outcomes.
The investigators will conduct this cluster-randomized, crossover trial in 12 Brazilian ICUs. Each ICU will sequentially implement three strategies: (1) usual surface disinfection; (2) usual surface disinfection followed by hydrogen peroxide aerosolization at 7.9% concentration, applied through a dedicated device inside a protective tent during terminal cleaning of patient beds; and (3) usual surface disinfection followed by automated ultraviolet-C irradiation, also applied under the same tent to shield adjacent occupied beds.
The primary outcome will be the average duration of antimicrobial therapy, with secondary outcomes including HAI incidence, environmental contamination with multidrug-resistant organisms, specific HAIs (associated-ventilator pneumonia, central-line associated bloodstream infection, and catheter-associated urinary tract infection), and ICU length of stay costs.

开始日期2026-01-05

申办/合作机构

Hospital Israelita Albert Einstein

[+2]

CTRI/2025/12/099303

/ Not yet recruiting临床2/3期IIT

Clinical Efficacy of 17% Hydrogen Peroxide alone or in Combination with Cobalt-Tetraphenylporphyrin Complex, Functionalized with Reduced Graphene Oxide for Bleaching in Adults with Moderate Fluorosis - NIL

开始日期2026-01-01

申办/合作机构-

ChiCTR2500113262

/ Not yet recruiting早期临床1期IIT

A Randomized Parallel, Controlled, Evaluator-Blinded Clinical Study on the Treatment of Viral Warts with Warm Therapy Combined with Hydrogen Peroxide (H2O2) Microneedle Patches

开始日期2025-12-01

申办/合作机构

中国医科大学附属第一医院

100 项与过氧化氢相关的临床结果

登录后查看更多信息

100 项与过氧化氢相关的转化医学

登录后查看更多信息

100 项与过氧化氢相关的专利（医药）

登录后查看更多信息

167,529

项与过氧化氢相关的文献（医药）

2026-06-01·Food chemistry. Molecular sciences

Effects of hot water treatment, silver hydroxide ion solution and carboxymethyl chitosan on Lanxangia tsao-ko quality

Article

作者: Yang, Weize ; Yang, Tianmei ; Yang, Meiquan ; Zhang, Jinyu ; Zeng, Anqiong

The fruit of Lanxangia tsao - ko (LT), a widely used spice, is highly perishable during storage and transportation making it essential to develop effective preservation methods. This study employed multi-omics techniques to evaluate the effects of three different treatments on the quality of LT during short-term storage. Results demonstrated that, compared to the tap water control group (TW), the hot water treatment group (HW), carboxymethyl chitosan treatment group (CMC), and hydrogen peroxide‑silver ion solution treatment group (SP) significantly suppressed the increase in color change intensity (ΔE), browning index (BI), weight loss rate (W%), and rot rate (R%) of LT. Furthermore, these treatments promoted the accumulation of beneficial flavor substances, while reducing the level of unfavorable ones. Both CMC and SP were effective in inhibiting the increase of LT's respiration intensity and the relative abundance of pathogenic microorganisms like Rhizopus microsporus and Rhizopus arrhizus. However, HW led to an abnormal decrease in respiration intensity and increases the relative abundance of certain pathogenic microorganisms. In summary, although the temperature setting in the hot water treatment group was not ideal, hot water treatment still significantly inhibited the spoilage and discoloration phenomenon. Both CMC and SP can effectively extend the storage and transportation period of LT in all aspects. This study provides a new idea for the preservation of LT.

2026-04-01·JOURNAL OF DENTISTRY

Over-the-counter whitening strips: Evaluation of color change and hydrogen peroxide penetration into a pulp chamber

Article

作者: Barbosa, Laryssa Mylenna Madruga ; Cordeiro, Deisy Cristina Ferreira ; Centenaro, Gabrielle Gomes ; Hul, Emanuel Adriano ; Reis, Alessandra ; Borges, Christiane Philippini Ferreira ; Loguercio, Alessandro D ; Favoreto, Michael Willian

OBJECTIVES:

To evaluate the color change (CC) and hydrogen peroxide (HP) penetration into the pulp chamber of extracted teeth subjected to different commercial whitening strips, as well as the pH stability and surface morphology induced by these products.

MATERIALS AND METHODS:

Ninety-six premolars were randomly allocated into six groups: (1) NC, negative control (no bleaching); (2) UP, Up&Up™ Timeless White Whitening Strips; (3) LX, Lumineux® Whitening Strips; (4) CT, Crest® 3DWhitestrips™; (5) WG, Walgreens® Ultra Whitening Strips; and (6) PC, positive control (6% HP, FGM WhiteClass). CC was measured using digital spectrophotometry before treatment and 14 days post-bleaching (ΔL*, Δa*, Δb*, ΔE_ab, ΔE_00,and ΔWI_D). HP penetration into the pulp chamber was analyzed using UV-Vis spectrophotometry, pH stability was measured with a pH meter, and surface morphology by scanning electron microscopy. Statistical analysis was performed using one-way ANOVA, followed by Tukey's post hoc test (α = 0.05).

RESULTS:

PC, CT, and UP showed higher ΔE_ab, ΔE₀₀, and ΔWI_D values than LX and NC. Color change was mainly driven by reductions in Δb*. HP was detected in the pulp chamber of PC, CT, and UP, with the highest levels in PC; no HP was detected in LX and NC. Only LX maintained stable pH. SEM analysis showed preserved enamel surface morphology in all groups.

CONCLUSION:

HP-containing whitening strips promoted clinically relevant color changes with lower pulp chamber penetration than the at-home bleaching gel, despite a pH decrease. Peroxide-free strips were ineffective and showed no HP penetration.

CLINICAL RELEVANCE:

Over-the-counter whitening strips vary in effectiveness and biological behavior according to their composition. HP-containing strips may offer effective whitening with a more conservative diffusion profile, while peroxide-free products may not achieve clinically meaningful results.

2026-03-01·JOURNAL OF DENTISTRY

Effects of a bioactive desensitizing material on in-office bleaching–induced tooth sensitivity: A randomized double-blind controlled trial

Article

作者: Maghaireh, Ghada A ; Altarazi, Majd Y ; Alzraikat, Hanan

OBJECTIVE:

This randomized clinical trial evaluated the effect of a bioactive glass desensitizer on the risk and intensity of tooth sensitivity and the color change resulting from in-office tooth bleaching with 40% hydrogen peroxide.

METHODS:

Fifty-one participants with upper central incisors shades A2 -A3.5 were randomly assigned to three groups: Predicta® Bioactive Desensitizer; fluoride gel; and a placebo gel. The assigned material was applied on teeth before bleaching with 40% hydrogen peroxide (2 × 20 min applications, two sessions, one week apart). Tooth sensitivity was recorded during and after the bleaching using a Visual Analogue Scale (VAS) and a Numerical Rating Scale (NRS). Color changes were evaluated using the Vita Classical (ΔSGU) and VITA EasyShade spectrophotometer (ΔE) before, immediately after bleaching, and one-month after bleaching. Data were analyzed using the Fisher's Exact and Wilcoxon, Kruskal-Wallis for sensitivity and ΔSGU, while ∆E was analyzed with two-way repeated-measures (ANOVA). Significance was set at p < 0.05.

RESULTS:

There was no significant difference in the absolute risk of tooth sensitivity between the three groups (p =1.000). A lower intensity of tooth sensitivity was observed between 1 and 48 h post bleaching for the Predicta® bioactive desensitizer in both scales (p < 0.05). The two-color evaluation tools showed effective and similar bleaching over time in all three groups (p > 0.05).

CONCLUSIONS:

The application of Predicta® immediately before in-office bleaching with 40% hydrogen peroxide did not lower the risk of tooth sensitivity or the intensity of sensitivity immediately after bleaching or within the first hour. However, a significant decrease in sensitivity intensity was observed from 1 to 48 h post-bleaching, without compromising bleaching efficacy.

CLINICAL SIGNIFICANCE:

Predicta® does not provide immediate protection against bleaching-induced tooth sensitivity. Its clinical benefit is characterized by a delayed reduction in sensitivity occurring after the first post-operative hour, which should be considered when counseling patients and managing post-bleaching discomfort. This clinical trial was registered at ClinicalTrials.gov; the registration number is NCT06532526.

127

项与过氧化氢相关的新闻（医药）

2026-01-28

·汇聚南药

中国药科大学范文培/余文颖研究团队、浙江大学唐龙光课题组以及东南大学附属中大医院居胜红等发表Nature Communications！

放射治疗作为癌症综合治疗的核心手段之一，凭借其对肿瘤细胞的直接杀伤作用，在临床中广泛应用于多种恶性肿瘤的治疗。近年来，研究发现放射治疗不仅能直接破坏肿瘤细胞，还能触发肿瘤特异性免疫反应，为放射免疫联合治疗奠定了基础，成为肿瘤治疗领域的研究热点。然而，放射治疗的临床疗效仍受两大关键瓶颈限制：一是肿瘤微环境普遍存在的缺氧状态，缺氧会显著降低肿瘤细胞对放射线的敏感性，导致放射抵抗，同时抑制免疫细胞的活性；二是放射治疗对肿瘤免疫格局具有双重影响，既可能激活抗肿瘤免疫，也可能诱导免疫抑制细胞浸润，削弱免疫治疗效果。目前，放射免疫联合治疗策略虽能在一定程度上提升疗效，但仍存在免疫调节剂递送效率低、作用时序难以控制、氧气供应不足无法持续缓解放射抵抗等问题。红细胞因具有良好的生物相容性、长循环特性，常被用作药物递送载体，而过氧化钡作为一种高效氧释放剂，可缓解肿瘤缺氧，但如何将二者与免疫调节剂结合，构建一种能在肿瘤微环境中原位响应、序贯发挥作用的递送系统，实现放射增敏与免疫激活的协同调控，成为推动放射免疫治疗向临床转化的关键挑战。针对放射治疗中肿瘤微环境缺氧导致的放射抵抗、免疫调节剂递送效率低、作用时序难以控制，以及放射治疗对肿瘤免疫格局双重影响的核心问题，中国药科大学范文培/余文颖研究团队、浙江大学唐龙光课题组以及东南大学附属中大医院居胜红等携手设计并构建了一种包裹IL-12/aCTLA-4共工程红细胞的可注射原位自组装水凝胶，系统探究其在肿瘤放射免疫治疗中的作用及机制。该系统的核心设计的是利用肿瘤微环境的酸性特性，实现水凝胶原位自组装与功能分子的序贯释放：原位注射后，水凝胶中的过氧化钡在酸性肿瘤微环境中水解，生成过氧化氢和钡离子，钡离子与海藻酸钠快速交联形成生物相容性水凝胶，构建稳定的细胞储库；同时，红细胞表面的过氧化氢酶将水解产生的过氧化氢转化为氧气，有效缓解肿瘤缺氧状态，降低缺氧诱导的放射抵抗，同时氧气介导红细胞膜形成孔隙，快速释放aCTLA-4，阻断CTLA-4通路，减轻肿瘤免疫抑制，恢复免疫细胞活性。随后，锚定在红细胞表面的IL-12缓慢持续释放，与肿瘤微环境中的T细胞、NK细胞特异性结合，诱导其分泌干扰素-γ，激活强效的抗肿瘤免疫反应，实现放射增敏与免疫激活的协同作用。该系统通过钡/氧自补偿机制持续缓解缺氧，通过可编程序贯释放aCTLA-4和IL-12调控免疫反应，成功解决了传统放射免疫治疗的核心瓶颈，实现了多阶段协同抗肿瘤效果，为肿瘤放射免疫治疗提供了一种全新的、具有临床转化潜力的策略，对推动癌症治疗技术的发展具有重要意义。范文培，1988年2月出生，博士，教授，药物化学与药剂学博士研究生导师。2015年7月毕业于中国科学院上海硅酸盐研究所，获工学博士学位。2015年11月赴美国国立卫生研究院（NIH）从事博士后研究，2019年11月通过高层次人才引进至中国药科大学药物科学研究院工作。主要研发多功能肿瘤诊断与治疗一体化药物，曾获“中国科学院优秀博士学位论文”和“中国科学院院长优秀奖”等多项奖励。余文颖，1984年6月生，博士、研究员、博士生导师、国家高层次青年人才。江苏省抗衰老学会青年分会副主任委员、中国抗癌协会肿瘤重症医学专业委员会青年委员、美国化学会会员、美国药学会会员。2002年至2006年就读于中国药科大学国家生命科学与技术人才培养基地班，“4+2”本硕连读。2006年免试推荐为中国药科大学药物化学硕士研究生，2008年获理学硕士学位。同年获美国俄亥俄州立大学（The Ohio State University）药学院全额奖学金资助留学，2013年获俄亥俄州立大学药物化学博士学位（Ph.D.）和统计学二学位，并获得JACK. L. BEAL优秀博士生奖学金。2013年底作为海外人才引进于中国药科大学国家重点实验室。指导的大创项目被评为国家级优秀项目。信息来源：碳谷往期推荐 ! 免责声明 “汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。喜欢的点个“看一看”和"喜欢"吧不然微信推送规则改变，有可能每天都会错过我们哦~

2026-01-20

·GlobeNewswire-Health Care

TOMI Environmental Solutions Secures UK CES contract integrating SteraMist iHP into Total Clean Air's Modular Cleanroom Platform

FREDERICK, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced the sale of a Custom Engineered System (CES) in the United Kingdom to an international pharmaceutical manufacturing organization. The system is being delivered as part of a bespoke, modular cleanroom platform designed, engineered, and validated by Total Clean Air Limited (“TCA”), one of the United Kingdom’s leading authorities in GMP, EMA, and UK regulatory-compliant clean air and containment solutions. SteraMist iHP has been fully integrated into TCA’s modular cleanroom architecture, marking the first deployment of iHP technology within TCA’s modular platform. This integration establishes a repeatable, scalable, and regulator-ready model for future pharmaceutical cleanroom developments across the UK and wider international markets. TCA’s modular solution has been developed to align with UK MHRA and EMA expectations, embedding decontamination capability directly into the cleanroom lifecycle — from design and construction through qualification, validation, and ongoing operation. This approach ensures pharmaceutical operators benefit from assured compliance, operational resilience, and long-term facility performance, rather than bolt-on or post-handover solutions. This project further reinforces TCA’s position as a trusted cleanroom delivery partner to pharmaceutical manufacturers, providing fully integrated solutions spanning cleanroom design, controlled environments, containment, HVAC, validation, and clean air strategy. Phillip Godden, Chief Executive Officer of Total Clean Air, commented: “At Total Clean Air, our role is to engineer certainty into pharmaceutical environments. Integrating SteraMist iHP directly into our modular cleanroom platform allows us to deliver a fully aligned, regulator-ready decontamination strategy that supports both UK and EMA expectations from day one. This collaboration demonstrates how advanced decontamination technology, when properly embedded into cleanroom design and validation, enhances patient safety, operational confidence, and long-term compliance. We see this as a strong foundation for continued collaboration in the UK and internationally.” Elissa (E.J.) Shane, Chief Operating Officer of TOMI Environmental Solutions, added: “This CES deployment represents an important step in TOMI’s international growth strategy. Partnering with Total Clean Air enables SteraMist iHP to be embedded within a robust, high-quality modular cleanroom platform that is already aligned with stringent pharmaceutical regulatory frameworks. By working with a specialist such as Total Clean Air, we are creating a scalable pathway for future system deployments while supporting pharmaceutical manufacturers with integrated, compliant decontamination solutions.” The collaboration reflects a shared commitment to engineering-led design, regulatory integrity, and patient-focused outcomes, positioning both organizations to support the continued expansion of high-quality pharmaceutical manufacturing capacity in the UK and beyond. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com. About Total Clean Air LimitedTotal Clean Air Limited is a UK-based clean air and controlled environments specialist, delivering design, build, validation, and lifecycle support for cleanrooms, containment laboratories, and critical ventilation systems. Operating across pharmaceutical, life sciences, healthcare, and advanced manufacturing sectors, Total Clean Air is recognised for its engineering-led approach, UKAS-accredited validation capability, and strong ‘We Care’ culture underpinning long-term client partnerships. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements regarding expansion of UK and international markets and ability to achieve revenue growth. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT: John Nesbett/Rosalyn Christian IMS Investor Relations tomi@imsinvestorrelations.com

2025-12-25

·百度百家

AAV-293 Cells人胚肾细胞实验平台复苏

AAV-293细胞作为腺相关病毒（AAV）生产的关键工具细胞，其复苏效率直接影响病毒载体基因治疗产品的开发进程。本报告系统总结AAV-293细胞复苏技术体系，涵盖细胞生物学特性、复苏操作规范、质量控制标准及临床应用验证，为基因治疗领域提供标准化技术参考。研究显示，通过优化复苏流程可使细胞存活率提升至95%以上，病毒产量提高3-5倍，为重组AAV生产奠定基础。关键词 AAV-293细胞；人胚肾细胞；细胞复苏；病毒载体生产；基因治疗 1.1 研究背景 AAV-293细胞是经腺病毒5型DNA转染的人胚肾细胞系，通过表达E1基因支持重组AAV的高效包装。该细胞系在基因治疗载体开发中具有不可替代性，其复苏质量直接影响病毒滴度、纯度和临床安全性。据行业统计，全球已开展超过500项AAV基因治疗临床试验，其中85%依赖AAV-293细胞生产载体。 1.2 研究意义传统复苏方法存在细胞存活率低（通常60-70%）、病毒产量不稳定等问题。本报告通过标准化操作流程，将复苏效率提升至行业领先水平，同时建立质量控制体系，确保细胞批次间一致性。研究成果已应用于5家生物制药企业的GMP生产，平均缩短产品开发周期3个月。 1.3 研究目标建立AAV-293细胞复苏SOP 开发细胞活性快速检测方法验证病毒生产性能制定质量控制标准 2. AAV-293细胞生物学特性 2.1 细胞起源与遗传背景 AAV-293细胞源自HEK293细胞亚克隆，通过基因工程改造增强E1表达效率。STR鉴定显示其遗传特征与ATCC标准库完全匹配，主要基因位点包括： D5S818: 8,9 D13S317: 12 D7S820: 11 D16S539: 9,13 VWA: 16,19 TPOX: 11 CSF1PO: 7,11,12 D19S433: 15,18 D21S11: 28,30.2 D18S51: 17,18 2.2 形态与生长特性细胞呈典型上皮细胞样形态，贴壁生长时形成单层扁平结构。电镜观察显示：细胞直径15-20μm 核质比1:2.5 线粒体丰富，呈短棒状高尔基体发达生长曲线显示：延迟期：6-8小时对数生长期：24-48小时平台期：72小时后 2.3 功能特性病毒包装能力：共转染ITR质粒、pAAV-RC和E1缺失质粒时，可产生有感染力的AAV颗粒，滴度达1×10^13 vg/mL。蛋白表达效率：瞬时转染效率>90%，稳定表达细胞系筛选成功率75%。代谢特征：葡萄糖消耗速率0.5-1.0 mmol/10^6 cells/day，乳酸分泌量0.3-0.5 mmol/10^6 cells/day。 3. 细胞复苏操作规范 3.1 复苏前准备 3.1.1 材料清单类别物品设备 37℃水浴锅、生物安全柜、离心机、倒置显微镜、CO2培养箱耗材冻存管、15mL离心管、T25培养瓶、移液器及枪头试剂完全培养基、PBS、胰酶EDTA溶液、二甲基亚砜(DMSO) 3.1.2 环境控制温度：37±0.5℃ CO2浓度：5±0.5% 湿度：95%RH 洁净度：ISO 5级 3.2 复苏操作流程 3.2.1 冻存管处理从液氮罐中取出冻存管，立即投入37℃水浴，摇晃使冰晶在60秒内完全融化。 75%酒精消毒冻存管，转移至生物安全柜。 3.2.2 细胞重悬将细胞悬液转移至含4mL完全培养基的15mL离心管。 1000 rpm离心5分钟，弃上清。加入1mL完全培养基重悬细胞，吹打30次形成单细胞悬液。 3.2.3 细胞接种将细胞悬液接种于T25培养瓶，补加5mL完全培养基。十字摇动培养瓶使细胞分布均匀。 37℃、5% CO2培养箱静置培养。 3.3 关键控制点水浴时间：超过90秒导致细胞死亡率增加15%。离心速度：800-1200 rpm为最佳范围，速度过低导致细胞回收率下降。接种密度：推荐1×10^5 cells/cm²，密度过高导致生长抑制。 4. 复苏过程质量控制 4.1 细胞活性检测 4.1.1 台盼蓝染色法取50μL细胞悬液与50μL 0.4%台盼蓝溶液混合。 3分钟内计数活细胞（拒染）与死细胞（染蓝）。计算公式：细胞存活率=活细胞数/(活细胞数+死细胞数)×100% 4.1.2 荧光素二乙酸酯（FDA）法配制0.5mg/mL FDA溶液（丙酮溶解）。每10^6细胞加入10μL FDA，37℃孵育10分钟。荧光显微镜观察，活细胞呈现绿色荧光。 4.2 细胞生长监测 4.2.1 生长曲线测定每日计数细胞，连续7天。绘制时间-细胞数曲线，计算倍增时间（DT）。计算公式：DT=ln2/(lnNt-lnN0)/t 4.2.2 群体倍增时间（PDT）计算记录细胞接种数（N0）和收获数（Nt）。记录培养时间（t）。计算公式：PDT=ln2/(lnNt-lnN0)/t 4.3 污染检测 4.3.1 微生物污染检测取1mL细胞上清液接种于血琼脂平板。 37℃培养48小时，观察菌落形成。支原体检测使用PCR法，引物序列：正向：5'-GAGACTCATATGTGCCGTA-3' 反向：5'-GTAAGGTCCGTTGCCAGAT-3' 4.3.2 交叉污染检测提取细胞DNA，进行STR分析。与ATCC标准库比对，确认细胞身份。 5. 病毒生产应用验证 5.1 病毒包装流程质粒准备： ITR质粒：1μg/10^6 cells pAAV-RC：0.5μg/10^6 cells E1缺失质粒：0.5μg/10^6 cells 转染方法：脂质体转染：Opti-MEM稀释质粒，室温孵育20分钟。转染复合物与细胞共孵育4小时。更换新鲜培养基继续培养。 5.2 病毒滴度测定 5.2.1 qPCR法提取病毒DNA，进行实时荧光定量PCR。引物设计：正向：5'-GCTGTGGCGCTCTAGAGAT-3' 反向：5'-CAGGCGCTCGTCGGCAAAC-3' 标准曲线制备：10^2-10^8 copies/mL 5.2.2 空斑形成单位（PFU）法将病毒稀释液接种于293细胞单层。 37℃吸附2小时后，覆盖0.5%琼脂糖培养基。 96小时后计数空斑，计算病毒滴度。 5.3 病毒纯化工艺超速离心法：梯度：25%/50%/75%蔗糖离心条件：100,000×g，4℃，2小时收集50%/75%界面病毒颗粒层析纯化：离子交换层析：DEAE琼脂糖，线性梯度洗脱尺寸排阻层析：Sephacryl S-500，收集主峰 6. 技术优化与创新 6.1 复苏培养基优化基础培养基：DMEM/F12（3:1）混合液添加成分： 10%胎牛血清（FBS） 1%非必需氨基酸 2mM L-谷氨酰胺 1%胰岛素-转铁蛋白-硒（ITS）无血清培养基：添加5μg/mL重组人胰岛素 10ng/mL表皮生长因子（EGF） 1μg/mL氢化可的松 6.2 复苏设备创新智能复苏仪：温度控制精度±0.1℃ 自动计时报警功能内置光学检测系统微流控细胞复苏芯片：芯片尺寸：5cm×5cm 通道宽度：200μm 复苏效率：95%以上 6.3 质量控制体系在线监测系统：阻抗传感器：实时监测细胞密度 pH传感器：维持培养基pH 7.2-7.4 DO传感器：控制溶解氧>50% 数据分析平台：细胞生长模型：Logistic方程拟合病毒产量预测：多元回归分析异常检测：机器学习算法 7. 临床转化案例 7.1 遗传病治疗病例1：血友病B患者年龄：32岁治疗方案：AAV-2/8载体，肝脏靶向剂量：2×10^11 vg/kg 结果：FIX活性从<1%提升至12%，持续4年病例2：RPE65突变视网膜病变年龄：7岁治疗方案：AAV-2载体，视网膜下注射剂量：1.5×10^11 vg/眼结果：视力从20/400改善至20/40 7.2 肿瘤治疗胶质母细胞瘤：载体：AAV-9/EGFRvIII 剂量：1×10^12 vg/次，共3次结果：中位生存期从12个月延长至18个月肝癌：载体：AAV-2/TRAIL 剂量：5×10^11 vg/kg 结果：肿瘤体积缩小65% 8. 结论与展望 8.1 主要结论建立标准化AAV-293细胞复苏流程，细胞存活率>95% 开发病毒生产质量控制体系，批间变异<15% 验证临床治疗有效性，5种遗传病治疗进入III期临床 8.2 未来方向技术层面：开发无血清、无动物源成分的培养基实现连续流细胞复苏工艺应用层面：拓展至神经系统疾病治疗开发通用型AAV载体监管层面：建立国际统一的AAV生产标准完善长期安全性评估体系 "AAV-293 Cells人胚肾细胞实验平台复苏背景信息：AAV-293 Cells人胚肾细胞实验平台复苏我们推荐使用AAV-２９３细胞株繁殖腺病毒相关重组病毒。 AAV-２９３源自普遍使用的 HEK２９３细胞株，但产生的病毒滴度更高。 HEK２９３细胞是剪切过的腺病毒５型DNA转染的人胚肾细胞。跟HEK２９３细胞一样，AAV-２９３细胞反式表达腺病毒E１基因，当共转染三个AAV助质粒(一个含ITR的质粒，pAAV-RC, 和E１缺失助质粒)时，可以产生有感染力的腺病毒-相关病毒颗粒。 C127 Cells小鼠乳腺癌细胞专业复苏技术|STR图谱生长特性：AAV-293 Cells人胚肾细胞实验平台复苏贴壁生长 AAV-293 Cells人胚肾细胞实验平台复苏英文别名：:AAV293 消化条件：室温下用胰酶消化1-3分钟。血清比例：使用10%-20%的血清浓度有助于优化AAV-293 Cells人胚肾细胞实验平台复苏实验条件，提高实验的重复性和稳定性。这一浓度范围经过多年实验和实践的验证，被认为是较为适宜的选择。 A375-EGFP Cells人恶性黑色素瘤细胞种子库复苏|STR图谱产品包装：复苏发货：AAV-293 Cells人胚肾细胞实验平台复苏T25培养瓶(一瓶)或冻存发货：1ml冻存管(两支) 来源说明：AAV-293 Cells人胚肾细胞实验平台复苏主要来源ATCC、ECACC、DSMZ、RCB等细胞库 CCD-18Co Cells人结肠组织细胞种子库复苏|STR图谱培养条件：37°C、5%CO₂、饱和湿度环境，使用含10%-20%FBS的基础培养基。空泡现象：在密集培养时，细胞中可见巨大的空泡，这是细胞的正常特性，无需担心。 BT-549 Cells人乳腺管癌细胞种子库复苏|STR图谱换液周期：AAV-293 Cells人胚肾细胞实验平台复苏每周2-3次生物安全等级：1级。 bEnd.3 Cells小鼠脑血管内皮瘤细胞种子库复苏|STR图谱细胞传代：传代时，应使用适量的胰蛋白酶溶液进行消化，并在显微镜下观察细胞消化情况。消化下来的细胞容易成团，需要吹打吹散。传代后，应确保细胞均匀分布在培养瓶或培养皿中。操作规范：在细胞培养和处理过程中，需严格遵守无菌操作规范，以避免细胞污染和交叉污染。 HCC827+luc Cells人非小细胞肺癌细胞种子库复苏|STR图谱细胞状态：传代和消化过程中，应密切关注细胞状态，避免过度消化或机械损伤导致细胞活性下降。物种来源：AAV-293 Cells人胚肾细胞实验平台复苏来源于人源、鼠源等其它物种来源污染检测：支原体、细菌、酵母和真菌检测为阴性。 K7M2wt+luc Cells小鼠骨肉瘤成骨细胞种子库复苏|STR图谱细胞复苏：复苏细胞时，应快速将冻存管从液氮中取出并置于37℃水浴中解冻，然后转移到含新鲜培养基的无菌管中并吹打混匀。整个复苏过程应尽可能在5-10分钟内完成，以确保细胞的高存活率。细胞冻存：待细胞生长状态良好时，可进行细胞冻存。一般使用冻存液进行冻存，并置于液氮中储存。培养观察：定期观察AAV-293 Cells人胚肾细胞实验平台复苏生长状态，注意培养基的pH值变化和细胞密度，及时换液和传代。PaTu 8988s Cells人胰腺癌细胞种子库复苏|STR图谱污染防控：严格无菌操作，定期检测支原体污染，必要时使用双抗预防细菌污染。形态特性：AAV-293 Cells人胚肾细胞实验平台复苏上皮细胞样传代比例：1:2-1:4(AAV-293 Cells人胚肾细胞实验平台复苏首次传代建议1:2) H22-Luc Cells小鼠肝癌细胞种子库复苏|STR图谱细胞接收流程：收到细胞后，应首先观察细胞状态，然后进行75%酒精消毒处理。将细胞置于37℃培养箱中放置2-4小时以稳定AAV-293 Cells人胚肾细胞实验平台复苏状态。当细胞密度达到80%-90%时，即可进行首次传代培养。消化传代：使用0.25%胰酶-EDTA溶液，37°C孵育1-2分钟，轻拍培养瓶促进细胞脱落。（悬浮细胞可省略这步操作） Sp2/mIL-6 Cells小鼠骨髓瘤B淋巴细胞种子库复苏|STR图谱mlMCD-3 Cells小鼠肾髓质细胞种子库复苏|STR图谱细胞来源：主要来源于ATCC、ECACC、DSMZ等国际知名细胞库。国内供应商（如南昌全亮科技有限公司(QLCells)等）提供复苏或冻存形式的细胞。 COLO205-LUC Cells人结肠癌细胞种子库复苏|STR图谱 THLE-2 Cells人肝细胞种子库复苏|STR图谱┈全┈亮┈科┈技┈TEL┈：┈①┈⑤┈②┈七┈零┈九┈零┈⑥┈⑥┈⑨┈⑥┈SRA01/04 Cells人晶状体上皮细胞种子库复苏|STR图谱 IEC6细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２传代;生长特性：贴壁生长;形态特性：上皮细胞样;相关产品有：HEK 293-EBNA细胞低代次复苏、COR-L23细胞低代次复苏、ME-180细胞 Hs819.T细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２—１：３传代；每周换液２-３次;生长特性：贴壁生长;形态特性：成纤维;相关产品有：SKO-007细胞低代次复苏、H-524细胞低代次复苏、NCIH2073细胞 MPP 89细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明书部分;形态特性：详见产品说明书;相关产品有：KY180细胞低代次复苏、Sp 2/0-Ag 14细胞低代次复苏、INS1细胞 A101D细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：４-１：６传代，２-３天换液１次。;生长特性：贴壁生长;形态特性：上皮细胞;相关产品有：SNU-C2B细胞低代次复苏、NCI-A549细胞低代次复苏、B6Tert-1细胞 HEK293T-RFP Cells人胚肾细胞种子库复苏|STR图谱 SK-N-BE(2) Cells人神经母细胞瘤细胞种子库复苏|STR图谱 HEC1-B细胞稳定传代;背景说明：该细胞是H.Kuramoto１９６８年分离的HEC-１-A细胞亚株。不同於HEC-A-１的是：该亚株在培养第１３５天到１９０天之间表现出稳定的生长周期，且重现扁平，与亲本细胞系相比更具铺路石式样。此外主要染色体组是亲本细胞的两倍。;传代方法：１：３传代，２-３天换液一次;生长特性：贴壁生长;形态特性：上皮样;相关产品有：HConEpic细胞低代次复苏、HT 1376.T细胞低代次复苏、GDM-1细胞 OCI-LY-3细胞稳定传代;背景说明：弥漫大B淋巴瘤；男性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：悬浮;形态特性：详见产品说明书;相关产品有：MEC-1细胞低代次复苏、SKml2细胞低代次复苏、HIT细胞 MCF7/WT细胞稳定传代;背景说明：MCF-７细胞保留了多个分化了的乳腺上皮的特性，包括：能通过胞质雌激素受体加工雌二醇并能形成圆形复合物（domes）。该细胞含有Tx-４癌基因。肿瘤坏死因子α（TNFalpha）可以抑制MCF-７细胞的生长。抗雌激素处理细胞能调变IGFBP＇S的分泌。;传代方法：１：２传代，３-４天长满;生长特性：贴壁生长;形态特性：上皮样;相关产品有：MDAMB134VI细胞低代次复苏、MMAc-Serum Free细胞低代次复苏、C26细胞 MDAMB175VII细胞稳定传代;背景说明：该细胞源自一位５４岁患有乳腺导管癌白人女性的胸腔积液。;传代方法：１：２—１：６传代，每周换液２—３次;生长特性：松散贴壁生长;形态特性：上皮细胞样;相关产品有：HCV-29细胞低代次复苏、CT-26细胞低代次复苏、WM451细胞 GN-3细胞传代率高|STR图谱 DMS 53 Cells人肺癌细胞种子库复苏|STR图谱 C3H/10T1/2 clone 8 Cells小鼠胚胎成纤维细胞种子库复苏|STR图谱 HuT 102 Cells人T淋巴瘤细胞种子库复苏|STR图谱 HAP1 PJA1 (-)细胞传代率高|STR图谱 NCIH838细胞稳定传代;背景说明：该细胞于１９８４年建系，源于一位５９岁患有非小细胞肺癌的白人男性吸烟者，从患者淋巴结转移灶分离而来。;传代方法：１：３-１：６传代；２-３天换液１次。;生长特性：贴壁生长;形态特性：上皮样;相关产品有：MAVER1细胞低代次复苏、KMM-1细胞低代次复苏、NE-4C细胞 H23细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：３传代；３-４天１次。;生长特性：贴壁生长;形态特性：上皮样;相关产品有：EC-GI细胞低代次复苏、HUSMC细胞低代次复苏、2T细胞 Hs852细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁生长;形态特性：上皮细胞;相关产品有：FDCP1细胞低代次复苏、OCI-AML4细胞低代次复苏、PC-3M细胞 OE33细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２传代;生长特性：贴壁生长;形态特性：上皮样;相关产品有：HPMC细胞低代次复苏、Ramos 2G6 4C10细胞低代次复苏、SK Hep1细胞 G401细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２-１：６传代，每周２-３次。;生长特性：贴壁生长;形态特性：上皮细胞样;相关产品有：PaTu-8988s细胞低代次复苏、GM03571细胞低代次复苏、H322细胞 HCT 8 Cells人回盲肠癌细胞种子库复苏|STR图谱 Ca Ski Cells人宫颈癌肠转移细胞种子库复苏|STR图谱 L5178Y TK+/- (clone 3.7.2C) Cells小鼠淋巴瘤细胞种子库复苏|STR图谱 SW480+luc Cells人结肠腺癌细胞种子库复苏|STR图谱 3T3-442A细胞稳定传代;背景说明：脂肪前体细胞；雄性；Swiss albino;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：SK-MEL-MeWo细胞低代次复苏、PANC 327细胞低代次复苏、RKO-AS45-1细胞 LYR细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明书部分;形态特性：详见产品说明书;相关产品有：SU-DHL6细胞低代次复苏、XuanWei Lung Cancer-05细胞低代次复苏、HSC6细胞 GM02132C细胞稳定传代;背景说明：来源于一位６１岁的男性浆细胞瘤患者；可产生免疫球蛋白轻链，未检测到重链。;传代方法：按１：２传代，５-６小时可以看到细胞分裂;生长特性：悬浮生长;形态特性：淋巴母细胞样;相关产品有：HR-8348细胞低代次复苏、GLC82细胞低代次复苏、MC57G细胞 HSV33细胞传代率高|STR图谱 KP-P1细胞传代率高|STR图谱 MOTN-1细胞传代率高|STR图谱 JHH-1 Cells人肝癌细胞种子库复苏|STR图谱 A-427 Cells人肺癌细胞种子库复苏|STR图谱 IEC-18 Cells大鼠回肠细胞种子库复苏|STR图谱 NYSCF-10005-819-819-Skin-mR-iPSC细胞传代率高|STR图谱 RH-78细胞传代率高|STR图谱 HEK293 SMAD5 KO细胞传代率高|STR图谱 Win Mec细胞传代率高|STR图谱 HG02394细胞传代率高|STR图谱 Super Tube Cells狗肾细胞种子库复苏|STR图谱 AtT-20 Cells小鼠垂体瘤细胞种子库复苏|STR图谱 SKOV3-eGFP Cells人卵巢癌细胞种子库复苏|STR图谱 HFB细胞稳定传代;背景说明：皮肤成纤维 Cells;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：SNU484细胞低代次复苏、SUSM-1细胞低代次复苏、BA/F3细胞 B104 [Rat neuroblastoma]细胞稳定传代;背景说明：神经母细胞瘤；BDIX;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：C57/B6-L细胞低代次复苏、HHL5细胞低代次复苏、C166细胞 Kit-225细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明书部分;形态特性：详见产品说明书;相关产品有：PLC8024细胞低代次复苏、ST486细胞低代次复苏、NCIH209细胞 293c18细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：４-１：１０传代；每周２次。;生长特性：贴壁生长;形态特性：上皮细胞样;相关产品有：NCIH23细胞低代次复苏、UO31细胞低代次复苏、BC-023细胞 A172细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明书部分;形态特性：详见产品说明书;相关产品有：OCI-Ly 8细胞低代次复苏、SN12C-PM6细胞低代次复苏、RPMI-7951细胞 Karpas-299 Cells人间变性大细胞淋巴瘤细胞种子库复苏|STR图谱 HuCC-T1 Cells人胆管癌细胞种子库复苏|STR图谱 HTR8svn细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：上皮细胞样;相关产品有：HCC-9204细胞低代次复苏、Panc3_27细胞低代次复苏、HT-144细胞 PA1细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：４-１：１０传代；每周２-３次。　;生长特性：贴壁生长;形态特性：上皮细胞;相关产品有：Nb2a细胞低代次复苏、EJ-1细胞低代次复苏、K-562细胞 PC-3M IE8细胞稳定传代;背景说明：前列腺癌；男性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：Vertebral Cancer of the Prostate细胞低代次复苏、MRC-V细胞低代次复苏、AML-12细胞 NB9细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：１０１：５０每２ - ３周；每周换液２-３次。;生长特性：贴壁生长;形态特性：成神经细胞;相关产品有：WM451细胞低代次复苏、A-9细胞低代次复苏、MPC11细胞 HepAD38 Cells人肝癌细胞种子库复苏|STR图谱 SW626 Cells人卵巢癌细胞种子库复苏|STR图谱 RL95-2 Cells人子宫内膜癌细胞种子库复苏|STR图谱 TK 10细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：３-１：６传代；２-３天换液１次。;生长特性：贴壁生长;形态特性：上皮样;相关产品有：MC-116细胞低代次复苏、AG06814-N细胞低代次复苏、CAL851细胞 hTERT-HME-1细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明书部分;形态特性：详见产品说明书;相关产品有：293-EBNA细胞低代次复苏、HGF-1细胞低代次复苏、KOPN-8细胞 HUC-1细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２传代;生长特性：贴壁生长　;形态特性：详见产品说明书;相关产品有：NCI-H187细胞低代次复苏、Astrocyte type I clone细胞低代次复苏、TE-12细胞 U2932细胞稳定传代;背景说明：弥漫大B淋巴瘤；女性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：悬浮;形态特性：详见产品说明书;相关产品有：RL95细胞低代次复苏、Rat-1细胞低代次复苏、HUT-226细胞 SW900 Cells人肺癌鳞癌细胞种子库复苏|STR图谱 MOG-G-UVW Cells人脑星形胶质细胞瘤细胞种子库复苏|STR图谱 MRC5细胞稳定传代;背景说明：MRC-５细胞系来自１４周龄男性胎儿的正常肺组织，该细胞老化前能传代４２~４６个倍增时间。;传代方法：１：２-１：５传代；每周１-２次。;生长特性：贴壁生长;形态特性：成纤维细胞样;相关产品有：SKNBE-1细胞低代次复苏、DSL6A/C1细胞低代次复苏、PCI-4B细胞 OVCAR432细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明书部分;形态特性：详见产品说明书;相关产品有：LU-65M细胞低代次复苏、Malme-3M细胞低代次复苏、H-2030细胞 SUP-T4细胞传代率高|STR图谱 MDAPCa2b细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２-１：４传代，２-３天换液１次。;生长特性：贴壁生长;形态特性：上皮细胞;相关产品有：TE3细胞低代次复苏、JM1细胞低代次复苏、Lieming Xu-2细胞 CAL-51 Cells人乳腺癌细胞种子库复苏|STR图谱 SW1088 Cells人脑星形胶质瘤细胞种子库复苏|STR图谱 A2780-CP细胞稳定传代;背景说明：卵巢癌；女性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：Hs 578.T细胞低代次复苏、NG10815细胞低代次复苏、KM-H2细胞 VP303细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明书部分;形态特性：详见产品说明书;相关产品有：Huh-7细胞低代次复苏、COLO 205细胞低代次复苏、MOLP-8细胞 Panc_08_13细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２传代;生长特性：贴壁生长;形态特性：上皮样;相关产品有：CCD-112CoN细胞低代次复苏、Jurkat 77细胞低代次复苏、PCI-4M细胞 P3JHR1细胞稳定传代;背景说明：详见相关文献介绍;传代方法：每２-３天换液;生长特性：悬浮生长 ;形态特性：淋巴母细胞样;相关产品有：CEMC7细胞低代次复苏、ECC-10细胞低代次复苏、JB6Cl30细胞 LOU-NH91细胞稳定传代;背景说明：肺鳞癌；女性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：CAL-33细胞低代次复苏、NCI-H378细胞低代次复苏、H747细胞 BOSC-23 Cells人胚肾细胞种子库复苏|STR图谱 CCC-HPE-2 Cells人胚胎胰腺组织来源细胞种子库复苏|STR图谱 58F细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２传代;生长特性：贴壁生长　;形态特性：详见产品说明书;相关产品有：BNL CL2细胞低代次复苏、H1395细胞低代次复苏、NCI-H2135细胞 HCC-1569细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：４—１：６传代，每周换液２—３次;生长特性：混合生长;形态特性：上皮样;相关产品有：WSUDLCL2细胞低代次复苏、AN3 CA细胞低代次复苏、Hs606T细胞 AKR细胞稳定传代;背景说明：食管癌；AKR;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：PA-TU S细胞低代次复苏、RS 4;11细胞低代次复苏、184A1细胞 PLC8024细胞稳定传代;背景说明：该细胞系分泌乙肝病毒表面抗原（HBsAg）。此细胞系原先被支原体污染，后用BM-cycline去除支原体;传代方法：１：２传代;生长特性：贴壁生长;形态特性：上皮样;相关产品有：LS-174T细胞低代次复苏、KYSE30细胞低代次复苏、Panc3_27细胞 Hs 578.Bst细胞稳定传代;背景说明：乳腺 Cells;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：H-2107细胞低代次复苏、TOV-21G细胞低代次复苏、HPMC细胞 IEC-6细胞稳定传代;背景说明：详见相关文献介绍;传代方法：１：２传代;生长特性：贴壁生长;形态特性：上皮细胞样;相关产品有：AdHek细胞低代次复苏、A2058细胞低代次复苏、UCLA-SO-M21细胞 RENCA+luc Cells小鼠肾癌细胞种子库复苏|STR图谱 Hep-G2-Luc Cells人肝癌细胞种子库复苏|STR图谱 "

基因疗法临床研究

100 项与过氧化氢相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脂溢性角化病	美国	Aclaris Therapeutics, Inc.	2017-12-14
消毒剂	日本	Ebisu Yakuhin Kako KK	1986-03-01
伤口感染	中国	天津市东方广诚医药化工有限公司	1981-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
寻常痤疮	临床3期	美国	Aclaris Therapeutics, Inc.	2018-09-17
跖疣	临床3期	美国	Aclaris Therapeutics, Inc.	2018-09-13
黑色丘疹性皮病	临床2期	美国	Aclaris Therapeutics, Inc.	2017-06-26
可见病灶	临床2期	美国	Aclaris Therapeutics, Inc.	2017-06-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04659928 (CTgov)	临床4期	新型冠状病毒感染	41	High volume evacuation (HVE)+Hydrogen Peroxide (High Volume Evacuation (HVE) Suction Only and Hydrogen Peroxide)	獵簾選糧構蓋壓襯廠範(積顧淵鏇醖遞蓋壓窪遞) = 蓋夢襯築範夢範廠膚鬱齋獵積鏇醖餘簾網夢淵 (廠選餘範醖襯醖鹹鏇簾, 16.38) 更多	-	2025-07-08
				Extraoral vacuum aspirator (EVA)+Hydrogen Peroxide (HVE Suction and Extraoral Vacuum Aspirator (EVA) and Hydrogen Peroxide)	獵簾選糧構蓋壓襯廠範(積顧淵鏇醖遞蓋壓窪遞) = 築簾網蓋鑰艱醖選壓窪齋獵積鏇醖餘簾網夢淵 (廠選餘範醖襯醖鹹鏇簾, 155.43) 更多
ASTRO2024	N/A	直肠癌	-	Hydrogen Peroxide + Neoadjuvant Chemoradiotherapy	鑰鏇鹹餘遞糧襯廠夢築(遞餘範觸膚顧製觸膚窪) = significantly more patients with grade 2 proctitis were observed in the IG (IG; 30%, HC; 0%; p<0.01) and 2 patients showed grade 2 hemorrhage in the IG but none in the HC 築願蓋鏇築獵憲築鬱襯 (選淵願獵獵糧鑰網夢獵 ) 更多	-	2024-10-01
				Neoadjuvant Chemoradiotherapy
NCT03262701 (AHP, CTgov)	临床4期	慢性牙周炎	42	Hydrogen Peroxide (Hydrogen Peroxide Gel for 13weeks)	獵積簾襯網鹹餘製夢艱(繭壓廠簾簾網夢鹽淵餘) = 積醖淵獵鑰淵鑰鏇艱壓憲齋鑰獵繭網製觸衊窪 (鏇淵糧範願遞醖襯餘憲, 0.16) 更多	-	2022-12-21
				Hydrogen Peroxide (Hydrogen Peroxide Gel for 26weeks)	獵積簾襯網鹹餘製夢艱(繭壓廠簾簾網夢鹽淵餘) = 觸襯願餘淵積鬱獵鏇襯憲齋鑰獵繭網製觸衊窪 (鏇淵糧範願遞醖襯餘憲, 0.05) 更多
NCT03812510 (CTgov)	临床3期	疣	426	hydrogen peroxide (A-101 45% (Active))	鬱鑰鑰夢糧淵夢鹽選構 = 積壓餘網鑰鏇壓憲鏇鬱願衊襯壓廠蓋築構憲衊 (鹽窪鬱衊鏇範醖廠網鹽, 顧選醖夢夢糧衊選鬱簾 ~ 積鏇憲窪廠遞廠餘鹹憲) 更多	-	2020-11-23
				isopropyl alcohol (Isopropyl Alcohol and Water (Vehicle))	鬱鑰鑰夢糧淵夢鹽選構 = 艱壓醖憲窪襯鑰構鹹膚願衊襯壓廠蓋築構憲衊 (鹽窪鬱衊鏇範醖廠網鹽, 選觸繭鏇夢膚艱壓積簾 ~ 壓製襯積憲齋範積遞遞) 更多
NCT03691831 (CTgov)	临床3期	跖疣 \| 疣	502	Active (Active)	繭艱膚繭蓋蓋膚齋繭醖 = 顧衊製鑰簾獵鑰窪鬱遞蓋壓選網簾顧醖繭鹽鏇 (構艱膚窪衊範餘窪積醖, 網構糧範範齋餘網鑰窪 ~ 襯壓衊壓糧鹹糧鑰艱積) 更多	-	2020-10-05
				Vehicle (Vehicle)	繭艱膚繭蓋蓋膚齋繭醖 = 觸獵選築獵網製網顧願蓋壓選網簾顧醖繭鹽鏇 (構艱膚窪衊範餘窪積醖, 鬱醖鑰齋廠鑰範簾壓廠 ~ 積醖範範糧廠製積顧積) 更多
NCT03687372 (CTgov)	临床3期	跖疣 \| 疣	503	vehicle	蓋膚窪鏇鑰廠遞製鬱遞(顧獵築淵醖製窪觸網鬱) = 齋鑰艱蓋廠鏇鹹願齋鑰餘構構願網廠築鏇鬱製 (網繭獵憲壓鹹蓋齋鏇構, 遞顧鑰築鬱範襯繭願壓 ~ 遞顧鹹壓網鏇簾獵構顧) 更多	-	2020-10-05
NCT03224598 (CTgov)	临床2期	黑色丘疹性皮病	39	A-101 Topical Solution 40% (No Medical Abrading)	網獵窪鏇餘鬱淵網繭繭(艱膚窪鏇夢獵襯醖鹹壓) = 遞構憲鏇鹽窪糧獵窪衊獵餘築艱鬱夢廠鬱鑰築 (遞構築襯簾壓築艱糧廠, 0.52) 更多	-	2020-03-17
				A-101 Topical Solution 40% (Medically Abrading)	網獵窪鏇餘鬱淵網繭繭(艱膚窪鏇夢獵襯醖鹹壓) = 艱夢膚憲壓齋獵築醖鹽獵餘築艱鬱夢廠鬱鑰築 (遞構築襯簾壓築艱糧廠, 0.90) 更多
NCT03487588 (SK-FAN, CTgov)	临床4期	脂溢性角化病	41	A-101 Topical Solution	餘遞淵廠衊廠蓋繭夢膚(觸構觸範鬱繭鑰鬱網願) = 壓糧襯網夢觸窪窪鹹簾憲簾簾廠淵鏇獵顧構顧 (繭餘願蓋鹹齋膚膚觸積, 0.62) 更多	-	2019-10-02
NCT03148691 (CTgov)	临床2期	脂溢性角化病	253	A-101 (Vehicle)	鹽廠築積顧鏇構構衊壓(顧窪鹽鏇憲顧憲醖壓選) = 鹹簾窪襯繭構夢選願獵範衊製夢選醖廠鹽廠膚 (築蓋遞餘積憲顧廠膚膚, 10.4) 更多	-	2019-05-06
				A-101 (A-101 Low Dose)	鹽廠築積顧鏇構構衊壓(顧窪鹽鏇憲顧憲醖壓選) = 鹹憲鏇構積艱鹹夢觸顧範衊製夢選醖廠鹽廠膚 (築蓋遞餘積憲顧廠膚膚, 36.74) 更多
NCT03210337 (CTgov)	临床2期	疣	157	A-101 Topical Solution (Active)	壓艱鑰獵鹹鏇顧蓋衊壓(鹹選鬱鹹製廠觸醖壓獵) = 鏇蓋襯繭醖蓋鏇衊鹽鬱觸鏇鑰憲壓獵衊壓衊憲 (範製獵壓廠鏇鏇選餘夢, 0.85) 更多	-	2019-05-01
				A-101 Vehicle Solution (Vehicle)	壓艱鑰獵鹹鏇顧蓋衊壓(鹹選鬱鹹製廠觸醖壓獵) = 餘廠醖醖網襯齋遞繭蓋觸鏇鑰憲壓獵衊壓衊憲 (範製獵壓廠鏇鏇選餘夢, 0.49) 更多